Expand RVMD Menu
RVMD MENU

RVMD Stock Posts


Unusual Option Volume

RVMD Revolution Medicines97.96-4.75 (-4.6%)

Revolution Medicines trades 8,788 contracts. The company has the following event: on Jan 8, 2026. News: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
View Details...
Unusual Option Volume

RVMD Revolution Medicines84.26+4.41 (+5.5%)

Revolution Medicines trades 3,676 contracts. The company has the following event: 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
View Details...
Upcoming Earnings

RVMD Revolution Medicines58.12-0.45 (-0.8%)

Revolution Medicines will report earnings after the market closes. View Calendar The market is expecting a ±9.0% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±5.0%. View Expected Move (Conf Call: Nov 5 4:30 PM)
RVMD #RevolutionMedicines stock increases 7.9% after hours.

After Hours Gainer

RVMD Revolution Medicines49.68+0.12+0.2%

After Hours:53.61+3.93 (+7.9%)

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Globe NewswireThu, 16-Oct 8:00 PM
RVMD #RevolutionMedicines stock increases 8.0% after hours.

After Hours Gainer

RVMD Revolution Medicines40.45-0.49-1.2%

After Hours:43.70+3.25 (+8.0%)

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Globe NewswireWed, 10-Sep 4:02 PM
RVMD #RevolutionMedicines stock increases 7.5% after hours.

After Hours Gainer

RVMD Revolution Medicines40.45-0.49-1.2%

After Hours:43.50+3.05 (+7.5%)

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Globe NewswireWed, 10-Sep 4:02 PM
Load Earlier Posts
Market Data Delayed 15 Minutes